Immune Repertoire Sequencing Market worth US$560.5 million by 2030 with 9.6% CAGR | MarketsandMarkets™ [Yahoo! Finance]
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Yahoo! Finance
to grow at a robust CAGR of 9.6%, reaching US$354.6 million in 2025 and an impressive US$560.5 million by 2030. Rapid technological advancements and growing demand for personalized and precision medicines drive the market. In addition, growing applications in autoimmune disease research, the increasing use of IRS in organ transplant monitoring, and a rising focus on immunotherapy also propel market growth. Moreover, the combination of AI and ML and growing applications in vaccine development has opened significant prospects for market growth. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151469626 Browse in-depth TOC on " Immune Repertoire Sequencing Market 450 - Tables 45 - Figures 400 - Pages By Based on product, the IRS market is divided into assay kits & reagents and instruments & software. The large share of the assay kits & reagents segment can be attributed to the growing demand for reproducibility and standardization in immune profiling
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- Illumina To Webcast Upcoming Investor ConferencePR Newswire
- Illumina (NASDAQ:ILMN) had its price target raised by analysts at JPMorgan Chase & Co. from $105.00 to $130.00. They now have a "neutral" rating on the stock.MarketBeat
- Illumina (NASDAQ:ILMN) had its "underweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Illumina (NASDAQ:ILMN) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually [Yahoo! Finance]Yahoo! Finance
ILMN
Earnings
- 10/30/25 - Beat
ILMN
Sec Filings
- 12/16/25 - Form 4
- 12/12/25 - Form 144
- 12/9/25 - Form 4
- ILMN's page on the SEC website